Biomarker Discovery & Validation

Utilizing cutting-edge technologies such as genomics, proteomics, and metabolomics, we identify and validate novel biomarkers that enhance disease diagnosis, prognosis, treatment response, and patient stratification in clinical development.

Multi-Platform Biomarker Analysis

Our CLIA-certified laboratories provide extensive biomarker analysis services, including flow cytometry, multiplex assays, and other high-throughput platforms, ensuring accurate patient selection and response monitoring.

Lab Developed Tests (LDT)

We perform and validat LDTs for a wide range of clinical applications, ensuring accuracy, precision, and clinical utility in diagnostic and therapeutic decision-making.

Companion Diagnostics (cDx)

Through strategic partnerships with biopharma companies, we develop and commercialize cDx tests, including IHC-based assays, to guide patient selection and optimize therapeutic outcomes.

Sponsored Testing Programs

We collaborate with biopharma companies to design and implement sponsored testing programs that support drug development, patient selection, and clinical decision-making, ensuring targeted and effective treatment strategies.

As a CLIA-certified laboratory, Axela Biosciences adheres to the highest regulatory and quality standards, ensuring reliable and reproducible results. By integrating advanced biomarker technologies and clinical expertise, we empower precision medicine, helping researchers and clinicians develop and apply personalized treatment approaches for better patient outcomes.